argenx

This #InternationalWomensDay, we’re celebrating our invaluable female Argonauts and highlighting how our industry can create more opportunities for #WomeninBiotech. #TogetherWeDiscover #IWD25

Today we announced that clinical trial and real-world data showcasing our focus on immunology innovation to drive autoimmune patient impact will be presented at the American Academy of Neurology (AAN) Annual Meeting in April.    Learn more: https://bit.ly/41yVRHY   #TogetherWeDiscover #AAN2025

Advocacy starts with a single voice but is strengthened through inclusion and community. Dawn and Vanetta of the Myasthenia Gravis Holistic Society know firsthand the power of support and representation within the myasthenia gravis (MG) community. As advocates, they work to ensure that no one, no matter their background, faces MG alone. Through outreach, support groups, and research sharing, they’re creating spaces where members of the MG community feel seen, heard, and empowered. As we close out #BlackHistoryMonth, the continued support and work to create an inclusive future and equal care for all remains critical. Learn more about the MG Holistic Society’s support here: https://bit.ly/4i0nSiQ #TogetherWeDiscover

Our full year and 2024 Q4 earnings report is now available. Together, we accelerated scientific discovery for patients worldwide, which included:    ➡️ Establishing commercial and clinical strategic priorities to advance Vision 2030, our goal of reaching 50,000 patients and 10 labeled indications by 2030    ➡️ Further demonstrating breadth and depth within our immunology pipeline, advancing multiple product candidates with potential across multiple high-need indications    ➡️ Continuing to invest in our Immunology Innovation Program (IIP) to drive long-term sustainable pipeline growth    Read more here: https://bit.ly/4kgTLoK   #TogetherWeDiscover 

Meet Clive: an inspiring member of the multifocal motor neuropathy (MMN) community leading the upcoming Tour de MMN. 🚴    This June, he’ll embark on a ride across France to raise MMN awareness and research funding for GBS|CIDP Foundation International. We’re proud to join him in this incredible effort and look forward to a special ride with him next month!   Learn more about our dedication to the MMN community: https://bit.ly/3XfNRdS   #TogetherWeDiscover

Vision 2030 is a bold path forward, rooted in meaningful innovation and a mission to reach more patients globally. As Board Member Don deBethizy highlights, our focus on science and development drives progress toward a future where we aspire to make an even greater difference for patients.    Learn how Vision 2030 is guiding our next chapter of innovation: https://bit.ly/4gMsVSo   #TogetherWeDiscover #HealthcareonLinkedIn 

As our Chief Operating Officer Karen Massey shares, we put patient needs at the center of all that we do – from the earliest stages of development to delivering innovative treatments. This Rare Disease Awareness Month, discover more about our patient-centric approach to address the unmet needs of the rare disease community: https://bit.ly/4hm2cNJ #TogetherWeDiscover #HealthcareonLinkedIn

Generalized myasthenia gravis (gMG) is a rare autoimmune condition affecting two to seven people in every 10,000. For people with gMG, disrupted nerve-muscle communication causes muscle weakness.     Discover more about gMG and our commitment to the patient community: https://bit.ly/3WwOAH2    #TogetherWeDiscover 

Through our Immunology Innovation Program (IIP), we developed ARGX-119 in collaboration with Dr. Steven Burden, Neurology Department at Massachusetts General Hospital and Harvard University, for patients with neuromuscular diseases, such as congenital myasthenic syndromes (CMS) and amyotrophic lateral sclerosis (ALS).    By integrating our antibody engineering expertise with deep disease biology insights, we aim to drive the development of novel treatments.     Read more of Professor Burden’s perspective on working with us to develop ARGX-119.    #TogetherWeDiscover 

Multifocal motor neuropathy (MMN) is a rare autoimmune condition characterized by slowly progressive muscle weakness, which can make everyday activities increasingly challenging. Discover more about our dedication to the MMN community: https://bit.ly/3CiySsg #TogetherWeDiscover